|
|
Find A Doctor
|
|
Ashraf
Z.
Badros, M.D., Ch.B.
Associate Professor of Medicine, Blood and Marrow Transplantation Program, UM Greenebaum Cancer Center
Department: Division Greenebaum Cancer Center: Blood and Marrow Transplantation (BMT) Greenebaum Cancer Center: Hematologic Malignancies Greenebaum Cancer Center: Hematology/Oncology Medicine: Hematology/Oncology
Special Interests: Myeloma; Stem Cell Transplantation
Medical Degree: Ain Shams University, Cairo, Egypt
Residency: Harbor Hospital Center, Medicine
Fellowship: Roswell Park Cancer Institute, Georgetown University, Oncology: Georgetown University, Bone Marrow Transplantation
Certification: Internal Medicine; Medical Oncology
Biography:Dr. Badros has extensive clinical experience in
Bone Marrow Transplantation with special interest
in multiple myeloma. He was involved in the
initial trails of thalidomide and has conducted
many clinical trials for treatment of relapsed
and refractory multiple myeloma. Dr. Badros research
has focused on evaluation of immunological approaches
to eradicate residual myeloma cells in the high-risk
setting following autologous stem cell transplantation
using natural killer (NK) and interleukin -2 (IL-2)
activated cells and non-myeloablative allogeneic
donor grafts.
Dr. Badros is involved in the development of
targeted novel therapeutics. He has completed a
gene therapy trial using G-3039 "Bcl-antisense."
He evaluated the use of the proteosome inhibitor
"bortezomib" in the newly diagnosed myeloma
patients and evaluated the effects of bortezomib
on stem cell. Currently, Dr. Badros is evaluating
various combinations of novel therapies in multiple
myeloma such as Lenalidomide and histone deacetylase
inhibitors (SAHA) in relapsed myeloma patients
alone and in combinations with dexamethasone and/or
bortezomib.
Ask Dr. Badros your multiple myeloma questions.
Contact Information:
1-800-373-4111 (physicians only)
1-800-492-5538 (patients and general information)
1-410-328-8919 (news media only)
|
|
|
|
|
|